(CNN) – The pharmaceutical giant Johnson & Johnson plans to start human clinical trials of its vaccine against the covid-19 in September, with the aim that the first batches are available to the authorization of emergency use at the beginning of next year, according to the announcement done by the company this Monday.
Johnson & Johnson noted that he has been working on a vaccine since January and has partnered in the project with the Research and Development Authority Biomedical Advanced (Barda, for its acronym in English), a division of the Department of Health and Human Services United States.
Johnson & Johnson and Barda will be committed to 1,000 million us dollars to finance the research, development and clinical testing of the vaccine, said the company.
“The world is facing a crisis of urgent public health and we are committed in doing our part to achieve that a vaccine covid-19 is available and is affordable at the global level as fast as possible,” said president and chief executive officer of Johnson & Johnson, Alex Gorsky, in a press release.
Johnson & Johnson will also expand its manufacturing capacity global to quickly produce the vaccine in case it is approved, he pointed out the pharmaceutical.
Now, Johnson & Johnson is not the only company in the race to create a vaccine as the pandemic of covid-19 spreads like a forest fire throughout the world.
The u.s. firm of Modern biotechnology sent his vaccine to researchers from the government to the test in February and the first dose is administered to trial participants at the beginning of this monthaccording to the National Institute of Allergy and Infectious Diseases.
Ben Tinker of CNN contributed to this report.